Weill Cornell Medical College in Qatar

Fairtility Launches AI Academy to Demystify Use of Artificial Intelligence in Fertility Care

Retrieved on: 
Tuesday, July 26, 2022

TEL AVIV, Israel, July 26, 2022 /PRNewswire/ -- Fairtility, the transparent AI innovator powering in vitro fertilization (IVF) for improved outcomes, announced the launch of the AI Academy, a new educational platform that will host healthcare and technology experts to engage the IVF community in the conversation around the responsible adoption of AI innovation in IVF care. 

Key Points: 
  • Fairtility launched the AI Academy at the European Society of Human Reproduction and Embryology (ESHRE) 38th Annual Meeting, which took place in Milan, Italy, July 3-6.
  • Dr. Gerard Letterie, a leader in reproductive endocrinology and infertility specialist at Seattle Fertility, serves as the Academic Head of the AI Academy.
  • "Our goal with the AI Academy is to provide the needed education, bringing IVF professionals into the conversation on AI transformation for fertility care.
  • For further information or to register for AI Academy, visit: www.fairtility.com/AIAcademy
    Fairtility is powering in vitro fertilization (IVF) through transparent AI to improve outcomes.

PLEXIUM APPOINTS BRIAN WONG, M.D., PH.D., TO ITS BOARD OF DIRECTORS

Retrieved on: 
Wednesday, July 13, 2022

SAN DIEGO, July 13, 2022 /PRNewswire/ -- Plexium, Inc. (Plexium), a leading next-generation targeted protein degradation (TPD) company, today announced the appointment of Brian Wong as a member of its Board of Directors.

Key Points: 
  • SAN DIEGO, July 13, 2022 /PRNewswire/ -- Plexium, Inc. (Plexium), a leading next-generation targeted protein degradation (TPD) company, today announced the appointment of Brian Wong as a member of its Board of Directors.
  • "We are very pleased to have such an accomplished executive and drug developer like Brian join our Board as we continue to advance our TPD pipeline toward the clinic and to patients in need," said Plexium President & CEO Percival Barretto-Ko.
  • "Plexium has tremendous potential to address the limitations of heterobifunctional degraders and cereblon IMiDsto create the next generation of Targeted Protein Degradation therapies," commented Dr. Wong.
  • I look forward to contributing to the Company's promising future as they advance novel TPD therapies toward the clinic."

Medscape Education to Host Nine Gastroenterology Symposia at Digestive Disease Week

Retrieved on: 
Thursday, May 19, 2022

NEW YORK, May 19, 2022 /PRNewswire/ -- Medscape Education will host nine educational symposia at Digestive Disease Week (DDW) 2022 in San Diego May 21- 24, estimated to reach 3,000 gastroenterology specialists attending the conference in person.

Key Points: 
  • NEW YORK, May 19, 2022 /PRNewswire/ -- Medscape Education will host nine educational symposia at Digestive Disease Week (DDW) 2022 in San Diego May 21- 24, estimated to reach 3,000 gastroenterology specialists attending the conference in person.
  • The live symposia will address key topics in gastroenterology including inflammatory conditions and infectious diseases, such as ulcerative colitis, Helicobacter pylori infection, hepatobiliary carcinoma, Crohn's disease, Clostridioides difficile, irritable bowel syndrome, and more.
  • More than 30 expert clinicians from diverse education and practice environments, including Cleveland Clinic and Weill Cornell Medical will participate as presenting faculty.
  • Medscape's staff of gastroenterology experts, working with world-renowned faculty, are poised to engage clinicians through interesting, relevant, and interactive sessions," said Douglas Kaufman, Group Vice President of Medscape Education.

Phosplatin Therapeutics Appoints Lorenzo Galluzzi, PhD, a Pioneer in Immunogenic Cell Death Research, to Scientific Advisory Board

Retrieved on: 
Thursday, March 24, 2022

NEW YORK, March 24, 2022 /PRNewswire/ -- Phosplatin Therapeutics Inc., a clinical stage pharmaceutical company focused on oncology therapeutics, today announced the appointment of Lorenzo Galluzzi, PhD, to the company's Scientific Advisory Board. Dr. Galluzzi leads the Galluzzi Lab at Weill Cornell Medical College in New York and is engaged in the development of the company's small molecule immunotherapy, PT-112, a potent immunogenic cancer cell death (ICD) inducer. Dr. Galluzzi is a highly-experienced leader in oncology research, teaching at top universities in the US and Europe and publishing extensively in scientific journals worldwide, with over 500 publications to date.

Key Points: 
  • Dr. Galluzzi leads the Galluzzi Lab at Weill Cornell Medical College in New York and is engaged in the development of the company's small molecule immunotherapy, PT-112, a potent immunogenic cancer cell death (ICD) inducer.
  • "We are excited for this new phase in our relationship with Dr. Galluzzi, who is world renowned for his research in immunogenic cell death in the field of oncology," said Phosplatin President and Chief Executive Officer Robert Fallon.
  • That study was published in a 2020 OncoImmunology paper titled "PT-112 induces immunogenic cell death and synergizes with immune checkpoint blockers in mouse tumor models."
  • The company's lead candidate, PT-112, is a novel chemical entity under clinical development that exhibits a unique combination of properties, including immunogenic cell death and osteotropism.

Orthopedic Shoulder, Elbow and Knee Specialist, Dr. Riley J. Williams III was once again awarded the Castle Connolly Top Doctors Award for 2022

Retrieved on: 
Friday, March 4, 2022

NEW YORK, March 4, 2022 /PRNewswire-PRWeb/ --Orthopedic surgeon and sports medicine specialist, Dr. Riley J. Williams III , was again awarded the Castle Connolly Top Doctors Award for 2022.

Key Points: 
  • NEW YORK, March 4, 2022 /PRNewswire-PRWeb/ --Orthopedic surgeon and sports medicine specialist, Dr. Riley J. Williams III , was again awarded the Castle Connolly Top Doctors Award for 2022.
  • Castle Connolly, the nation's trusted source for selecting Top Doctors for over 25 years, conducts a lengthy vetting process including peer nomination and Castle Connolly research.
  • Congratulations to Dr. Riley J. Williams III, for receiving the Castle Connolly's 2022 Top Doctor Award!
  • About Riley J. Williams III, MD: Dr. Riley Williams is an orthopedic knee, shoulder, and elbow specialist and an expert in the field of sports medicine.

New Nature Paper Relies on LUMICKS' C-Trap® Technology to Understand Functionality of Key Protein Involved with Incorrect DNA Repair of Dangerous Lesions Linked to Cancer Predisposition

Retrieved on: 
Tuesday, February 15, 2022

DSB repair is fundamental in maintaining the genome integrity and when compromised can lead to cancer predisposition.

Key Points: 
  • DSB repair is fundamental in maintaining the genome integrity and when compromised can lead to cancer predisposition.
  • The research, published in Nature (December 22, 2021), focused on protein HELQ, and was titled " HELQ is a dual-function DSB repair enzyme modulated by RPA and RAD51 ".
  • This revealed that HELQ is involved in many different branches of the DSB repair process and demonstrated how RPA and RAD51 differentially regulate its activity throughout the DNA repair process.
  • Similarly, the z-Movi Cell Avidity Analyzer enables the measurement and selection of immune cells based on their real-time interactions with target cells.

New Nature Paper Relies on LUMICKS' C-Trap® Technology to Understand Functionality of Key Protein Involved with Incorrect DNA Repair of Dangerous Lesions Linked to Cancer Predisposition

Retrieved on: 
Tuesday, February 15, 2022

DSB repair is fundamental in maintaining the genome integrity and when compromised can lead to cancer predisposition.

Key Points: 
  • DSB repair is fundamental in maintaining the genome integrity and when compromised can lead to cancer predisposition.
  • The research, published in Nature (December 22, 2021), focused on protein HELQ, and was titled " HELQ is a dual-function DSB repair enzyme modulated by RPA and RAD51 ".
  • This revealed that HELQ is involved in many different branches of the DSB repair process and demonstrated how RPA and RAD51 differentially regulate its activity throughout the DNA repair process.
  • Similarly, the z-Movi Cell Avidity Analyzer enables the measurement and selection of immune cells based on their real-time interactions with target cells.

Venture Investors Health Fund announces that Shelly Lanning has joined the firm as a Venture Partner

Retrieved on: 
Wednesday, December 15, 2021

MADISON, Wis., Dec. 15, 2021 /PRNewswire/ -- Venture Investors Health Fund, a leading early-stage health care investment firm, announced that Shelly Lanning has joined the investment team as a Venture Partner.

Key Points: 
  • MADISON, Wis., Dec. 15, 2021 /PRNewswire/ -- Venture Investors Health Fund, a leading early-stage health care investment firm, announced that Shelly Lanning has joined the investment team as a Venture Partner.
  • She was previously a Managing Director at HealthCor Venture Partners and an Executive Director at Morgan Stanley Venture Partners.
  • Her experience includes venture capital and growth equity investing, including M&A transaction expertise, corporate strategy, business development and financial.
  • Her extensive experience as a healthcare operator and investor will bring a valuable perspective to Venture Investors and the entrepreneurs we work with," said Jim Adox, Executive Managing Director, Venture Investors.